In a significant recall impacting the U.S. pharmaceutical market, 33,000 bottles of Metoprolol Succinate, a widely-used blood-pressure medication, are being retracted due to potentially dangerous manufacturing issues.
See the tweet below!
This recall follows the revelation of “failed dissolution specifications” during routine stability testing, raising questions about the drug’s effectiveness.
Granules India, the Hyderabad-based manufacturer, has acted promptly, but the implications raise concerns about pharmaceutical quality control.
Granules India, known for its wide range of generic medications, has initiated the recall of 33,024 bottles of Metoprolol Succinate extended-release tablets in the U.S. market.
This action was based on failed dissolution specifications detected during stability testing, which ensure a drug releases its active ingredient at the correct rate.
Failure in this regard suggests potential efficacy issues that may affect patient outcomes.
Granules Pharmaceuticals Inc., the U.S. division of the Indian conglomerate, has overseen the distribution of these potentially ineffective tablets across the nation.
The tablets, available in both 100-count and 500-count bottles, did not meet the necessary standards at the sixth-month mark of stability studies.
This lapse in quality control is alarming for patients relying on consistent therapeutic effects across each dose.
“Granules India is recalling over 33,000 bottles of Metoprolol Succinate, a generic blood pressure medication, in the US due to manufacturing issues,” the FDA said.
The FDA has labeled this a Class II recall, which indicates that “the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.”
Nonetheless, the revelation raises questions about the overall quality control standards in the pharmaceutical industry.
While Granules India’s swift response to initiate the recall on June 24 demonstrates compliance with regulatory standards, it serves as a stark reminder of the necessity for meticulous oversight in drug production.
Amidst this compliance, patients are advised to continue taking their medication as directed and consult their healthcare providers for further guidance.
Hyderabad-based Granules recalls over 33,000 bottles of blood lowering medication#Granules #USFDA #Pharmaceutical #drugRecallhttps://t.co/rWkVwuOCQw
— Telangana Today (@TelanganaToday) July 9, 2025
Pharmaceutical recalls such as this call attention to the critical need for rigorous quality assurance practices to ensure patient safety.
While the recall underscores Granules India’s commitment to addressing manufacturing issues, it also highlights the broader challenge of maintaining consistency in generic drug production.
